Artal Group S.A. Seagen Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $23.7 Million - $31.5 Million	-175,000 Reduced 33.33%	350,000 $47.9 Million
Q2 2022 Aug 11, 2022	SELL	$108.81 - $179.33 $13.6 Million - $22.4 Million	-125,000 Reduced 19.23%	525,000 $92.9 Million
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $17.9 Million - $23.7 Million	150,000 Added 30.0%	650,000 $93.6 Million
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $17.8 Million - $23.9 Million	125,000 Added 33.33%	500,000 $77.3 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $53.4 Million - $63.7 Million	375,000 New	375,000 $63.7 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.